Image-guided radiotherapy developer ViewRay said it has received approval from the China Food and Drug Administration for its MRIdian MRI-guided radiation therapy system.
MRIdian combines MR imaging with cobalt radiation delivery and software to create an MRI-guided radiation therapy system to treat cancers throughout the body, the company said. When clinicians use the system they can see soft tissue while adjusting the treatment dose in real-time. As a result, patients are spared the additional radiation dose common to other imaging modalities, ViewRay said.
China is one of the world's largest markets for medical devices, so approval by the China Food and Drug Administration is important to ViewRay's growth strategy, the company said. In China, ViewRay is represented by Cowealth Medical Holding.
